Lilly points in a new radiopharma direction
After being burned by Point, Lilly is taking a slower approach with Radionetics.
FDA green and red lights: June 2024
Merck and Daiichi’s first ADC attempt is knocked back, while Geron gets its inaugural approval.
Sutro reads the farletuzumab tea leaves
Farletuzumab ecteribulin follows its parent MAb with a setback, spelling possible bad news for Sutro.
Regeneron gets a European reprieve
The EU recommendation for odronextamab comes after a US rejection in March.
Bicara chases Merus
But ficerafusp is limited to HPV-negative disease, and petosemtamab’s safety looks better.
Immutep stumbles on into phase 3
Predictably Tacti-003 fails, but funding is secured – from investors, not a partner.
The month ahead: July’s upcoming events
Earnings season begins again, while big readouts loom for ALX and Fibrogen.
Merck’s big ADC deal takes a blow
A complete response letter for Merck & Co and Daiichi’s patritumab deruxtecan might not be fatal, but it’s certainly embarrassing.
